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HIGHLIGHTS
 The authors discuss the concept of atrial myopathy; its relationship to aging, electrophysiological remodeling, and
autonomic remodeling; the interplay between atrial myopathy, AF, and stroke; and suggest how to identify patients with
atrial myopathy and how to incorporate atrial myopathy into decisions about anticoagulation.
 Atrial myopathy seen in animal models of AF and in patients with AF is the result of a combination of factors that lead to
electrical and structural remodeling in the atrium. Although AF may lead to the initiation and/or progression of this
myopathy, the presence of AF is by no means essential to the development or the maintenance of the atrial myopathic state.
 Methods to identify atrial myopathy include atrial electrograms, tissue biopsy, cardiac imaging, and certain serum
biomarkers. A promising modality is 4-dimensional flow cardiac magnetic resonance. The concept of atrial myopathy may
help guide oral anticoagulant therapy in selected groups of patients with AF, particularly those with low to intermediate
risk of strokes and those who have undergone successful AF ablation. This review highlights the need for prospective
randomized trials to test these hypotheses.SUMMARYThis paper discusses the evolving concept of atrial myopathy by presenting how it develops and how it affects the
properties of the atria. It also reviews the complex relationships among atrial myopathy, atrial fibrillation (AF), and
stroke. Finally, it discusses how to apply the concept of atrial myopathy in the clinical setting—to identify patients with
atrial myopathy and to be more selective in anticoagulation in a subset of patients with AF. An apparent lack of a
temporal relationship between episodes of paroxysmal AF and stroke in patients with cardiac implantable electronic
devices has led investigators to search for additional factors that are responsible for AF-related strokes. Multiple animal
models and human studies have revealed a close interplay of atrial myopathy, AF, and stroke via various mechanisms
(e.g., aging, inflammation, oxidative stress, and stretch), which, in turn, lead to fibrosis, electrical and autonomic
remodeling, and a pro-thrombotic state. The complex interplay among these mechanisms creates a vicious cycle of ever-
worsening atrial myopathy and a higher risk of more sustained AF and strokes. By highlighting the importance of
atrial myopathy and the risk of strokes independent of AF, this paper reviews the methods to identify patients with
atrial myopathy and proposes a way to incorporate the concept of atrial myopathy to guide anticoagulation in
patients with AF. (J Am Coll Cardiol Basic Trans Science 2019;4:640–54) © 2019 The Authors. Published by Elsevier
on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).A trial fibrillation (AF) is the most commonarrhythmia in developed countries. Approxi-mately 2.3 million people in the United States
have been currently diagnosed with AF, and U.S.
Census projections estimate that this count will
more than double by 2050 (1). AF is associated with
a 5-fold risk of stroke, and AF-related strokes are
2.5-fold likely to be fatal (2). AF-related strokes are
usually attributed to clots forming in the left atrial
appendage (LAA) due to local stasis, followed by
dislodgement and embolization to the brain (particu-
larly upon restoration of sinus rhythm). However, this
classic concept has been challenged by observations
from clinical trials of the past 2 decades. If local stasis
during AF is the primary cause of stroke, maintenance
of sinus rhythm should prevent embolism. This wasnot what early randomized clinical trials such as
RACE (Rate Control versus Electrical Cardioversion
for Persistent Atrial Fibrillation Study) and AFFIRM
(Atrial Fibrillation Follow-up Investigation of Rhythm
Management) demonstrated 16 years ago (3,4).
Recently, several clinical studies in which patients’
atrial rhythms were continuously monitored showed
a temporal dissociation of the episodes of device-
recorded subclinical AF and stroke (5–8). For
instance, in the ASSERT (Asymptomatic Atrial Fibril-
lation and Stroke Evaluation in Pacemaker Patients
and the Atrial Fibrillation Reduction Atrial Pacing)
trial that enrolled 2,580 patients with cardiac
implantable electronic devices, only 8% of patients
with stroke had AF events detected within 30 days
before stroke, and 16% of patients with stroke had
ABBR EV I A T I ON S
AND ACRONYMS
4D = 4 dimensional
AF = atrial fibrillation
APD = action potential
duration
Ca2þ = calcium
CMR = cardiac magnetic
resonance
CRP = C-reactive protein
Cx = connexin




LA = left atrial




NOX2 = catalytic, membrane-
bound subunit of NADPH
oxidase
NT-proBNP = N-terminal pro
B-type natriuretic peptide
OAC = oral anticoagulant
ROS = reactive oxygen species
TGF = transforming growth
factor
TNF = tumor necrosis factor
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642their first AF event after their strokes (5). The
lack of a temporal relationship between the
onset of AF and stroke suggests that addi-
tional factors may be important contributors
to the occurrence of stroke and that the pres-
ence of AF is not necessary. The current para-
digm of selecting individuals at elevated risk
of stroke and who therefore warrant oral
anticoagulation (OAC) therapy, as endorsed
by major international societies (9,10), is by
the CHA2DS2-VASc score (congestive heart
failure, hypertension, age older than 75
years, diabetes mellitus, previous stroke, or
transient ischemic attack or thromboembo-
lism, vascular disease, age 65 to 74 years,
sex category), but not the properties of AF
per se (frequency, duration, ventricular
rates, and so on). All these risk factors are
known to cause atrial myopathy. There is
mounting evidence that supports that atrial
myopathy not only leads to stasis, but also
to endothelial and/or endocardial dysfunc-
tion and the hypercoagulable state, which
are 3 key factors in thrombogenesis described
by Virchow (11). AF may not be the root cause
of stroke, but rather, a marker that the atria
are diseased. This review seeks to: 1) intro-
duce the concept of atrial myopathy—
whether in the absence or presence of AF—
and highlight the recent translational andclinical studies that have investigated the relation-
ship among atrial myopathy, AF, and stroke; 2)
discuss how to identify patients with atrial myop-
athy, even in the absence of AF; and 3) discuss
whether severity of atrial myopathy can help guide
the decision to anticoagulate patients with AF.
ATRIAL MYOPATHY: THE CONCEPT
“. that the arrhythmia (AF) causes a
tachycardia-induced atrial cardiomyopathy
(myopathy) that results in electrophysiological
and anatomic remodeling of the atria.” (12)
Most of our mechanistic understanding of the atrial
myopathic state comes from research conducted
either in animal models of AF or from examination of
tissue removed from patients with a history of AF. In
1997, Zipes (12) first used the term “atrial myopathy”
to describe that AF can lead to myopathy through
atrial remodeling. The past 2 decades have seen the
concept of atrial myopathy evolving. Several recent
studies have demonstrated that the relationship be-
tween AF and atrial myopathy is more complex. Forexample, atrial myopathy may exist without AF and
can facilitate the development of AF (13). Anatomical
or structural changes, particularly fibrosis, play a
major role in the pathogenesis of AF, by increasing
the conduction heterogeneity in the atria, thereby
providing the substrate for re-entry (14–17). Atrial
interstitial fibrosis has been observed in patients with
AF (18). In dogs with heart failure induced by rapid
ventricular pacing, extensive atrial fibrosis underlies
the mechanism by which AF is much easier to be
induced and become sustained, despite unaltered
atrial electrophysiological parameters (19). Fibroblast
proliferation and extracellular matrix deposition in
response to insults such as aging (20), atrial stretch
(16), inflammation (21,22), and oxidative stress (21,23)
may predispose to anisotropy and re-entry (24). The
electrical derangement adds to a vicious cycle in
which “AF begets AF” (25)—rapid atrial myocyte de-
polarization leads to intracellular calcium accumula-
tion, triggering adaptive and inflammatory responses
that potentiate myocyte apoptosis and accelerate
atrial fibrosis (26).
Histologically, atrial fibrosis is characterized by
cardiomyocytes exhibiting loss of sarcomeres as well
as accumulation of glycogen storage granules, which
are adaptive alterations in cellular metabolism not
unlike those observed in response to ischemia (27). A
principal mediator of AF-induced atrial car-
diomyocyte apoptosis and necrosis is calpain (28), a
protein concentrated in or near the nucleus, and
intercalated discs, which are capable of both prote-
olysis and degradation of L-type calcium channels
(29). Other potential mediators of structural remod-
eling include platelet-derived growth factor, atrial
natriuretic peptide, and galectin-3 (30,31). In addi-
tion, the renin-angiotensin system appears to play a
role, because angiotensin-converting enzyme in-
hibitors (or angiotensin-receptor blockers) blunt
atrial fibrosis (32) and decrease the incidence of AF in
heart failure in both animal (33,34) and clinical
studies (35,36). Transforming growth factor-b (TGF-b)
also has an important role. Mouse models that over-
express TGF-b1 have profound atrial fibrosis and AF
(with normal ventricles) (15). In a canine model of
heart failure with extensive atrial fibrosis, the drug
pirfenidone significantly reduced atrial fibrotic
remodeling and vulnerability, and was associated
with a significant reduction in the expression of TGF-
b1 (37). In a canine heart failure model, Kunamalla
et al. (38) recently showed that targeted atrial
expression of a plasmid expressing a dominant
negative TGF-b1 receptor prevented atrial fibrosis,
with a resulting homogenization of conduction and a
decrease in inducible AF. To sum up, pathological
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which worsens the atrial myopathic processes that
then help to sustain more AF? The following sections
help to further highlight the concept that although AF
may lead to the initiation and/or progression of this
myopathy, the presence of AF is by no means essen-
tial to the development or the maintenance of this
myopathic state.
ATRIAL MYOPATHY AND THE AGING HEART
Aging leads to advancing decline in the structure and
function of the heart, and is a leading risk factor for
cardiovascular diseases (39), including AF. Although
50% of patients with AF are older than 80 years of age
(40), the molecular mechanisms that relate aging to
atrial deterioration remain partly elucidated, and it is
unclear how aging promotes atrial remodeling. Aging
is commonly associated with cardiovascular comor-
bidities, oxidative stress, calcium dysregulation,
atrial myopathy with apoptosis, and fibrosis, all of
which contribute to the initiation and/or mainte-
nance of AF, but the mechanisms have been poorly
explored (41). Chronic inflammation is associated
with several age-related diseases such as atheroscle-
rosis, Alzheimer’s disease, sarcopenia, and arthritis
(42). The genesis of chronic inflammation with aging
is unclear, but inflammation could be an underlying
mechanism that connects aging to atrial myopathy
and AF (43). Clinical studies have connected various
circulating inflammatory mediators, including C-
reactive protein (CRP), interleukin (IL)-1b, IL-6, tumor
necrosis factor (TNF)-a, and immune complement
activation, with persistent AF (44). Epicardial fat is a
major source of adipokines, inflammatory cytokines,
and free fatty acids, which contributes to fibrotic
remodeling within the atrial myocardium (45). Mac-
rophages and neutrophils are key cellular mediators
of inflammation that may contribute to AF by infil-
trating the atria or epicardial fat (46), releasing reac-
tive oxygen species (ROS), and producing
inflammatory cytokines, chemokines, metal-
loproteinases, or myeloperoxidases (43). Inflamma-
tion is also critical for insulin resistance in
experimental models of diet-induced obesity (47).
Increasing adiposity leads to the recruitment of
macrophages into fat depots. Macrophages, together
with adipocytes, generate inflammatory mediators,
including TNF-a, which may mediate insulin resis-
tance. Thus, inflammation occurs in aging, obesity
and AF, yet the inflammatory pathway linking obesity
to AF has not been identified.
Comprehensive understanding of the molecular
mechanisms of intrinsic cardiac aging, includingatrial aging, will be required to improve understand-
ing of the relationship among aging, inflammation,
atrial myopathy, and AF. Such new understanding
should guide the development and future translation
of novel therapies to clinical application. Mechanistic
insights may also identify other more specific thera-
peutic targets and provide guidance toward in-
terventions for AF-related comorbidities.
ATRIAL MYOPATHY AND
ELECTROPHYSIOLOGICAL REMODELING
Besides structural changes, atrial myopathy is asso-
ciated with alterations in calcium cycling (excita-
tioncontraction coupling), ion channels, and gap
junctions that, in turn, lead to electrophysiological
remodeling in the atrium.
Oxidative stress associated with atrial myopathy
leads to intracellular calcium overload, promoting
triggered activity and apoptosis. However, during AF,
the exceedingly high frequency of excitation of the
atria is expected to lead to ryanodine receptor type 2
refractoriness (48), as well as down-regulation of
calcium (Ca2þ) handling proteins (49), which act to
prevent triggered activity. Nevertheless, [Ca2þ]i
overload, together with atrial dilatation, mitochon-
drial ROS, and activation of inflammatory and
pro-fibrotic pathways, progressively alters gene
expression, with consequent myocyte hypertrophy,
interstitial fibrosis, and ion channel remodeling, all of
which occur slowly but reach critical levels when AF
becomes persistent (49).
The spatial distribution of ion channel functional
expression is heterogeneous throughout the atria
(50–52). In addition, the amount of remodeling ion
channels undergo with time in AF is also heteroge-
neous (53). Such heterogeneities are responsible for
the different electrophysiological properties of
different regions of the atria in terms of conduction
velocity, action potential duration (APD), and the re-
fractory period, all of which condition the ability of
each region to harbor re-entrant circuits at different
frequencies in response to the remodeling process.
Cellular electrophysiological studies in atrial myo-
cytes from patients in persistent or permanent AF
have revealed marked reductions in the densities of
the L-type voltage-gated Ca2þ current, the transient
outward potassium (Kþ) current, and the ultra-rapid
delayed rectifier Kþ current (54). Sustained high-
frequency excitation in a sheep model of long-term
atrial tachypacing led to APD abbreviation second-
ary to ion channel gene expression changes (the main
cardiac sodium channel, L-type calcium channel, and
voltage gated potassium channel decrease; and stria
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crease) (49). A study using specimens of human
atrium demonstrated that chronic AF reduced the
transient outward current and the ultrarapid delayed
rectifier potassium channel (IKur) (55). In addition, the
slow component of the delayed rectifier Kþ current is
increased, which results in significant APD abbrevia-
tion. Importantly, such changes are quantitatively
different between right and left atria, which may
explain the propensity of 1 atrium to sustain more
stable re-entry at a higher frequency than the other.
Gap junctions are essential in atrial conduction,
and gap junction remodeling, such as changes in
distribution, intercellular orientation, and expression
of gap junction proteins, is associated with electro-
physiological and structural changes that result in
sustained AF (56,57). Two major gap junction pro-
teins, connexin (Cx) 40 and Cx43, mediate
cardiomyocyte-to-cardiomyocyte electrical coupling.
Abnormal expression and heterogeneous distribu-
tions of Cxs have a strong association with AF in pa-
tients (58) and rapid pacing animal models (59,60). In
a dilated left atrium (LA) with chronic pressure
overload and left ventricular hypertrophy, reduced
expression and lateral distribution of Cx43, as well as
interstitial fibrosis, lead to conduction abnormality,
which increases the susceptibility to AF (61). More-
over, the laterally redistributed Cx43 does not form
gap junction channels (62). Together with the signif-
icant reduction in sodium current associated with
atrial remodeling (49), reduced Cx function should
significantly reduce atrial conduction velocity. In
patients with hypertension and left ventricular hy-
pertrophy but no history of AF, global conduction
slowing, focal conduction delay, and increased
vulnerability to AF have been noted (63). In a sub-
group of 485 patients from the ASSERT cohort (5),
serial noninvasive programmed atrial stimulation
showed those who went on to develop atrial tachy-
arrhythmias had P-wave prolongation and increased
vulnerability to AF induction at baseline but no dif-
ference in atrial refractoriness (64).
ATRIAL MYOPATHY AND
AUTONOMIC REMODELING
In addition to alterations in ion channels, gap junc-
tions, and excitationcontraction coupling, the auto-
nomic nervous system is another contributor to
electrical remodeling in the fibrillating atrium. Animal
studies have shown that atrial myopathy or LA
distention caused by obesity and obstructive sleep
apnea (65) can lead to remodeling of the autonomic
nervous system, which is instrumental inpathogenesis of cardiac arrhythmias (66), including
that of AF (67). Patterson et al. (68,69) described
“calcium transient triggering,” in that sympathetic
activation causes an increasing calcium transient (70),
whereas vagal activation can reduce the atrial effec-
tive refractory period (71). The discrepancy between
APD and the intracellular calcium transient, which are
normally tightly coupled, leads to an increased for-
ward sodium/Ca exchanger current, which contributes
to generation of early afterdepolarizations and trig-
gered activity (68). This is particularly evident in the
muscle sleeves of the pulmonary veins, of which focal
activities are critically important in the initiation of AF
in humans (72). Histologically, the pulmonary vein
muscle sleeves are particularly richly innervated with
both sympathetic and parasympathetic nerves (73,74).
With direct nerve recordings, the intrinsic cardiac
nerve activities recorded from the fat pad next to the
left superior pulmonary vein and LA junction were
found to be in close temporal relationships, with nerve
activities recorded from extracardiac nerve structures
(e.g., the left stellate ganglion and the thoracic vagus
nerve). Intrinsic cardiac nerve activities invariably
preceded spontaneously occurring atrial tachyar-
rhythmias in a canine model of pacing-induced AF
(75). In patients recovering from open heart surgery,
these fat pad intrinsic cardiac nerve activities were
associated with an increased burden of premature
atrial complexes and might predict the development
of post-operative AF (76).
ATRIAL MYOPATHY: ITS INTERPLAY
BETWEEN AF AND STROKE
One major link between atrial myopathy, AF, and
stroke is inflammation (77). Inflammatory markers,
such as CRP, TNF-a, and IL-2, -6, and -8, increase in
patients with AF (78). Several prospective epidemio-
logical studies confirmed that inflammation confers
an increased risk of AF. For example, in a large cohort
that involved 25,883 participants of the Women’s
Health Study, inflammatory biomarkers, including
CRP, soluble intercellular adhesion molecule-1, and
fibrinogen, were independently associated with
increased incidence of AF in initially healthy, middle-
aged women during a median follow-up of 14.4 years,
after controlling for traditional risk factors (79). In
another large cohort study of 47,000 subjects,
elevated plasma CRP levels were robustly associated
with increased incidence of AF (80). In the absence of
AF, it is possible that the pro-inflammatory state can
contribute to the development of atrial myopathy,
which, in turn, leads to endothelial dysfunction
or other structural changes, and thereby more pro-
CENTRAL ILLUSTRATION Atrial Myopathy: Its Relationship Between Atrial Fibrillation and Strokes
Shen, M.J. et al. J Am Coll Cardiol Basic Trans Science. 2019;4(5):640–54.
Atrial myopathy is typically caused by insults such as aging, inflammation, oxidative stress, and stretching of the atria. These myopathic changes alter the
properties of myocardial electrophysiology and cardiac autonomic nervous system. They can also lead to architectural structural changes characterized by
fibrosis. Furthermore, atrial myopathy results in endothelial dysfunction and stasis, thereby a prothrombotic state. Electrophysiological remodeling and
fibrosis facilitate the development of atrial fibrillation, which leads to more inflammation, fibrosis and autonomic remodeling, all of which contribute to a
worsening prothrombotic environment, mediated by circulating inflammatory cytokines, chemokines and other molecules such as C-reactive protein
(CRP), interleukin (IL)- 2, -6 and -8, tumor necrosis factor (TNF)-a, etc. Atrial fibrillation and thrombosis can develop separately and interact closely to
further aggravate the underlying atrial myopathic processes. CRP ¼ C-reactive protein; vWF ¼ von Willebrand’s Factor; WBC ¼ white blood cell.
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FIGURE 1 Stages of Atrial Myopathy
AF ¼ atrial fibrillation.
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647inflammatory (81). Once AF occurs, the inflammatory
state may help perpetuate AF, as evident by the
observation that CRP levels are higher in patients who
remained in AF, compared with those of patients who
converted to sinus rhythm (82). Inflammation might
also be involved in the creation of a pro-thrombotic
state during AF (83). In a cohort of 880 patients
with AF, CRP levels were correlated with risk of
stroke and all-cause mortality (84).
Inflammatory cells such as monocytes, macro-
phages, and lymphocytes produce cytokines and
chemokines and can trigger thrombosis in AF. One
such cytokine, IL-6, induces the expression of tissue
factor, fibrinogen, factor VIII, and von Willebrand
factor, mediating a pro-thrombotic state. It may also
cause endothelial activation and endothelial cell
damage, which leads to platelet aggregation and
sensitivity to thrombin (78). Activated platelets in
patients with AF could, in turn, promote and sustain
the pro-thrombotic state and increase inflammatory
biomarkers. Altered endothelial function also con-
tributes to inflammation and thrombosis in AF
(85,86). Upon endothelial activation, substances such
as von Willebrand factor and soluble P-selectin are
rapidly released onto the endothelial surface, pro-
moting the attachment of rolling white blood cells to
the endothelium and subsequently contributing
to the development of a pro-inflammatory and
pro-thrombotic environment. A recent interesting
discovery was that not only AF could promote
thrombosis, the hypercoagulable state itself pro-
moted atrial fibrosis and thereby facilitated AF, at
least in mouse models (87). OAC therapy might not
only prevent strokes but inhibit the development of a
substrate for AF. Another mechanism invoked in the
creation of atrial myopathy that is closely related to
inflammation is oxidative stress, in which ROS are
believed to modify the function of key ion channels
and Ca2þ cycling proteins (88–90), as well as acti-
vating pro-fibrotic signaling (91,92). The major source
of atrial ROS in patients with AF is NOX2, a
membrane-bound protein containing nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase
(93). Reilly et al. (94) showed that NADPH oxidase is
elevated early in AF (e.g., with post-operative AF),
with mitochondrial oxidases and uncoupled NO syn-
theses being noted in long-standing AF. Yoo et al. (95)
recently showed that ROS are preferentially elevated
in the posterior LA in a heart failure model of AF, with
a resulting increase in the substrate for both triggered
activity (by Ca2þ/calmodulin-dependent protein ki-
nase II phosphorylation of ryanodine receptor type 2)
and re-entry (via Ca2þ/calmodulin-dependent protein
kinase II phosphorylation of the main cardiac sodiumchannel). In response to oxidative stress, the
expression of growth differentiation factor 15 (GDF-
15) was shown to increase significantly (96). GDF-15
emerged as a novel biomarker to provide prognostic
information regarding cardiovascular events, beyond
traditional risk factors and other biomarkers, in pa-
tients with myocardial infarction (97) or heart failure
(98). Moreover, GDF-15 was also shown to be an in-
dependent risk factor for stroke in patients with AF
(99). After adjusting for potential clinical risk factors,
GDF-15 was associated with LAA thrombus in patients
with nonvalvular AF (100) (Central Illustration).
Figure 1 shows the proposed stages of atrial
myopathy (staging in line with 2013 American College
of Cardiology Foundation/American Heart Associa-
tion guidelines for heart failure [101]). With aging,
inflammation, atrial stretch from volume and/or
pressure overload, and oxidative stress, atria may be
at risk of developing atrial myopathy (stage A). At this
stage, clinical atrial myopathy is not detectable (see
the paragraph “How to identify patients with atrial
myopathy”). Once fibrosis and various ways of atrial
remodeling, including structural, electrophysiolog-
ical, and autonomic remodeling have taken place,
atrial myopathy is established and becomes detect-
able (stage B). At this stage, the individual remains
asymptomatic. Nevertheless, with ongoing inflam-
mation and remodeling, the myopathic atria become
manifest in the form of AF and stroke that typically
draw clinical attention. AF leads to a pro-thrombotic
state that feeds back to cause more AF by facili-
tating atrial fibrosis and inflammation. At stage C, the
manifest atrial myopathy can be reversed by aggres-
sive interventions such as lifestyle modification and a
successful AF ablation. If failure to reverse occurs, the
disease progresses to stage D, or end-stage atrial
myopathy. This illustration does not account for AF
being the initiating stimulus underlying the devel-
opment of the atrial myopathy. However, once
paroxysmal or chronic AF has led to the development
of some electrical and/or structural remodeling,
several of the paradigms suggested in Figure 1 would
again come into play to help perpetuate these
myopathic changes, potentially even in the absence
of the initiating stimulus (i.e., AF).
ATRIAL MYOPATHY: A LOGICAL
EXPLANATION TO THE LACK OF TEMPORAL
RELATIONSHIPS BETWEEN AF AND STROKE
Key observations, including the apparent inability of
AF rhythm control strategies to lower stroke risk (3,4),
and the lack of a strong temporal association between
paroxysmal AF and stroke in patients with prolonged
FIGURE 2 Atrial 4D Flow CMR in Patients With AF
(A) Atrial 4-dimensional (4D) flow cardiac magnetic resonance (CMR) for 2 patients with AF with comparable left atrial (LA) volume and identical CHA2DS2-VASc
scores ¼ 1 indicating low thromboembolic risk. Velocity histograms (C) quantify the LA velocity distribution inside the (B) LA. (D) LA stasis maps depict the relative
amount of low LA flow velocities (<0.2 m/s). Note the substantially increased flow stasis (red) in subject #51 compared with subject #35 despite identical CHA2DS2-
VASc scores. Ao ¼ aorta; LV ¼ left ventricle; PA ¼ pulmonary artery; RA ¼ right atrium; other abbreviation as in Figure 1.
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648rhythm monitoring via cardiac implantable electronic
devices (8,102,103) have heightened the search for
additional factors that could account for AF-related
strokes beyond the rhythm disturbance itself.
Although strokes may occur in the absence of AF itself,
AF burden is positively correlated with risk of stroke
(104). Furthermore, it has been recently reported that
patients with persistent or permanent AF have much
more thromboembolic events compared with those
with paroxysmal AF (105). If stroke can occur inde-
pendently of AF, how could more AF be associated
withmore strokes? One possibility is that these strokes
observed in clinical trials were not cardioembolic
strokes but rather strokes related to aortic, carotid. or
intracerebral atherosclerosis (106). A more likely
explanation is that the presence of atrial myopathy,
and its associated atrial remodeling (structural, elec-
trical, and autonomic), endocardial dysfunction and
pro-thrombotic state, may lead to cardioembolic
strokes without the necessity of fibrillating atria.
Higher AF burden (or persistent and/or permanent AF)
may merely reflect underlying more severe atrial
myopathy. In other words, the most logical explana-
tion to all these clinical observations is that atrial
myopathy facilitates the development of both AF and
stroke (in parallel, not in series). Atrial myopathy may
manifest periodically as AF but is always present andcontinually thrombogenic (107). Recent reviews
and editorials have suggested the importance of
atrial myopathy and have called for additional studies
of its role in AF and AF-associated complications
(106,108–110). The following section will discuss how
to identify patients with atrial myopathy and how to
apply the concept of atrial myopathy in guiding OAC
therapy in patients with AF.
ATRIAL MYOPATHY: TRANSLATING THE
CONCEPT INTO CLINICAL PRACTICE
HOW TO IDENTIFY PATIENTS WITH ATRIAL MYOPATHY.
Macroscopically, atrial myopathy may manifest as AF
or non-AF atrial arrhythmias, atrial dilatation,
impaired atrial systole, or abnormal cardiac imaging
findings (111). Therefore, several methods have been
reported to identify patients with atrial myopathy
and who are at risk of developing AF and AF-related
complications, particularly strokes.
Non-AF atrial arrhythmias, such as frequent atrial
premature beats or paroxysmal atrial tachycardia,
might indicate an abnormal atrial substrate and a
predisposition to AF, and have been associated with
increased risk of stroke in long-term follow-up, in-
dependent of diagnosed AF (112,113). Atrial electro-
grams acquired either noninvasively or invasively
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649may shed some light on underlying atrial myopathy
or potentially elevated thromboembolic risk, even in
the absence of AF. In a casecohort analysis of the
Northern Manhattan Study, which was a prospective
cohort study of stroke risk factors, P-wave terminal
force in lead V1 in sinus rhythm (a marker of LA ab-
normality) was associated with an increased risk of
cardioembolic stroke independently of the presence
of AF (114). Invasively, with high-density patch elec-
trodes in the LA in canines with healthy hearts and
pacing-induced heart failure with atrial fibrosis, the
atrial electrograms during induced AF were markedly
different: the overall AF electrograms in dogs with
heart failure (and extensive atrial fibrosis) were
slower and paradoxically more organized (115).
However, in the autonomic nerve-rich posterior LA,
the regional electrograms in dogs with heart failure
exhibited more spatial heterogeneity and were less
organized. Clinical and animal studies suggested that
regions of complex fractionated atrial electrograms
during AF might represent sites of high autonomic
innervation (75,116).
Imaging can be a useful tool in detecting patients
with atrial myopathy. Echocardiography (2 dimen-
sional, pulsed-wave Doppler, speckle-tracking echo,
strain and strain rate imaging) and cardiac computed
tomography are both useful in providing volumetric
and functional assessment of the LA (117,118). Larger
LA size, assessed by echocardiography, is associated
with a higher recurrence rate of AF after AF ablation
(119), and with an increased risk of recurrent stroke in
patients with nonvalvular AF and ischemic stroke
(120).
In recent years, cardiac magnetic resonance (CMR)
has become the gold standard of assessment of
chamber structure and function, mainly because of its
superiority in tissue characterization, particularly in
fibrosis. Delayed-enhanced CMR has been applied to
assess the extent of LA fibrosis and was found to be
correlated with surgical biopsy results and with AF
recurrence after catheter ablation (121,122). Further-
more, delayed-enhanced CMRdetected LA fibrosis
was found to be an independent risk factor of stroke,
after adjusting for other clinical risk factors, in pa-
tients with AF (123). Complimentary to this, a novel
noninvasive approach is atrial 4-dimensional (4D)
flow CMR, which provides a comprehensive charac-
terization of atrial flow dynamics that can overcome
limitations of transesophageal echocardiography. It
measures 3-D blood flow velocities with full coverage
of the LA and LAA, deriving stasis maps (124) that
provide intuitive visualizations and quantification of
stasis in the LA and LAA, the typical site of thrombus
formation (124–127). Moreover, 4-D flow CMR candetect physiological changes in LA hemodynamics in
AF and reveal an increased predisposition to atrial
thrombogenesis that is not discernible by the
CHA2DS2-VASc score (124,125,128,129). Figure 2 shows
data from 2 patients with AF and with identically low
CHA2DS2-VASc scores of 1 but substantially different
LA blood flow velocity histograms (Figure 2C) and
blood stasis maps (Figure 2D, color coded for an
intuitive visualization of stasis, where the red color
corresponds to a heightened risk for thrombogenesis).
Therefore, 4-D flow CMR-derived atrial stasis may
serve as an important new metric that measures
predisposition to atrial thrombogenesis that is not
captured with current clinical risk predictors and may
provide guidance in anticoagulation therapy in
selected groups of patients with AF.
Despite the promising data, several challenges
limit routine application for patients with AF. Beyond
the costs, a high level of expertise is required for
image acquisition and the time required for image
processing. Accurate 3-D imaging of the LA involves
manual segmentation from other images and careful
intensity threshold calibration to differentiate normal
from fibrotic tissue (130). Anatomic variability and
imaging artifacts may confound image processing.
Among the relevant patient factors are body size and
habitus that allow optimum image quality and
adequate heart rate control to facilitate gating.
HOW TO INCORPORATE THE CONCEPT OF ATRIAL
MYOPATHY IN GUIDING ANTICOAGULATION THERAPY.
Current guidelines endorsed the use of the CHA2DS2-
VASc score to guide anticoagulation therapy in pa-
tients with AF. Because stroke, as discussed earlier,
might occur independently of AF, individuals with an
elevated risk of stroke and no history of AF might be
identified and be protected by OAC therapy. The
CHA2DS2-VASc score was found to be valuable in
predicting stroke risk in the absence of AF. In patients
with heart failure and sinus rhythm, the CHA2DS2-
VASc score was found to provide prognostic infor-
mation on future stroke risk (131). Similarly, the
CHA2DS2-VASc score was associated with sponta-
neous echo contrast in the LA in patients with rheu-
matic mitral stenosis and no history of AF, who are at
risk of LA thrombus formation and thromboembo-
lism, despite being in sinus rhythm (132). On the other
end of the spectrum, with AF, the lack of key atrial
myopathic features might be helpful in identifying
individuals who do not require OAC therapy, thereby
sparing them the unnecessary risk of bleeding. The
current guidelines recommend no need for anti-
coagulation if the CHA2DS2-VASc score is 0 or 1, if
female. A logical integration of the concept of atrial
myopathy to the present paradigm would be to
Shen et al. J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 4 , N O . 5 , 2 0 1 9
Atrial Myopathy S E P T E M B E R 2 0 1 9 : 6 4 0 – 5 4
650examine the features of atrial myopathy in 2 groups of
patients: male with a CHA2DS2-VASc score of 1 and
female with a CHA2DS2-VASc score of 2. A review
article by Calenda et al. (107) proposed that in these 2
groups of individuals with AF, the lack of atrial
myopathic features might spare them of unnecessary
OAC therapy. Conversely, individuals with a low
CHA2DS2-VASc score but who have evidence of atrial
myopathy might benefit from OAC therapy. A pro-
spective, randomized clinical trial, ARCADIA (Atrial
Cardiopathy and Antithrombotic Drugs In Prevention
After Cryptogenic Stroke) sought to answer if OAC
therapy compared with daily baby aspirin would
prevent recurrent ischemic stroke in patients with
cryptogenic stroke who possess at least 1 marker of
atrial myopathy: an abnormal P wave, N-terminal pro
B-type natriuretic peptide (NT-proBNP) level, and
dilated LA on echocardiography (133).
Finally, observational studies showed that after a
successful AF ablation, the stroke risk might be sub-
stantially reduced and cessation of anticoagulation
might be safe in many patients (134,135). It is possible
that reverse remodeling can take place after a suc-
cessful AF ablation. Therefore, the assessment of
atrial myopathy after an AF ablation might aid in the
identification of individuals who no longer require
anticoagulation therapy. Conversely, failure of
reverse remodeling after an AF ablation might sup-
port a need for indefinite OAC therapy despite the
absence of AF recurrence. After AF ablation, elevated
circulating fibrocytes were found to serve as a marker
of LA fibrosis and predict the recurrence of AF (136). It
is possible that persistently elevated serum fibrocytes
may indicate the failure of reverse remodeling of an
underlying atrial myopathic process, which may be
continuously thrombogenic. Cessation of OAC ther-
apy in this group of patients might not be safe. This
hypothesis needs to be tested in prospective, ran-
domized trials.
Serum biomarkers can further improve risk strati-
fication for strokes beyond traditional risk factors.
Although generally not specific to atrial myocardial
disease, a growing body of evidence suggests that
serum biomarkers might be useful to quantify stroke
risk in patients with AF, in addition to clinical risk
factors. Various biomarkers correlated with myocyte
injury, oxidative stress, inflammation, and fibrosis(BNP, NT-proBNP, troponins, CRP, IL-6, among
others) have been reported to be elevated in AF or
predictive of development of AF (137) and linked to
outcomes in AF, including strokes (138). Using tro-
ponins and NT-proBNP, the novel biomarker-based
ABC (age, biomarkers, clinical history of stroke or
transient ischemic attack) stroke risk score system
has been shown to outperform the classic CHA2DS2-
VASc score system in both the derivation cohort
(c-statistic: 0.68 vs. 0.62) and in the validation cohort
(c-statistic: 0.66 vs. 0.58) (139).
CONCLUSIONS
Atrial myopathy characterized atrial fibrotic remod-
eling, together with electrical and autonomic remod-
eling, facilitates the development of both AF and
stroke. Various animal models of atrial myopathy,
such as a canine model of pacing-induced heart failure
and extensive atrial fibrosis (19), a mouse model that
overexpresses TGF-b1 (15), and a rat model of obesity
and artificially induced obstructive apnea (65), have
helped demystify the complex interplay between
atrial myopathy and AF. However, most animal
studies do not have long enough follow-up to further
determine a causal relationship between atrial myop-
athy and strokes. The chronicity of human clinical trial
data allows bridging of this gap, showing that in-
dividuals with markers of atrial myopathy have an
elevated risk of developing both AF and strokes
(84,99,112–114,123,140,141). Methods to identify
atrial myopathy include atrial electrograms, tissue
biopsy, cardiac imaging, and certain serum bio-
markers. A promising modality is 4-D flow CMR. The
concept of atrial myopathy may help guide OAC
therapy in selected groups of patients with AF,
particularly those with low-intermediate risk of
strokes (male with a CHA2DS2-VASc score of 1 and
female with a CHA2DS2-VASc score of 2) and those
who have undergone a successful AF ablation. Pro-
spective randomized trials are needed to test these
hypotheses.
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